- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04772248
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints
There are two main aims of this study.
First aim is to compare the risk of cardiovascular events (including myocardial infarction or stroke), between patients treated with tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA) among, 1) "real world evidence (RWE)" cohorts including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohorts including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.
Second aim is to examine the risk of myocardial infarction, stroke, heart failure hospitalization, coronary revascularization, and all-cause mortality as separate endpoints when comparing tofacitinib with TNFi in patients with RA among, 1) "real world evidence (RWE)" cohort including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohort including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
There will be two independent study populations:
- Real-World Evidence (RWE) cohorts: This study population will reflect the patients diagnosed with RA who are routinely treated and managed in setting of clinical practice.
- RCT-duplicate cohorts: This study population will emulate "the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis" clinical trial ("ORAL Surveillance", NCT02092467). The inclusion and exclusion criteria of this RCT will be applied to this study population.
Description
Criteria:
Please see https://www.bwhprime.org/resources.html for full code and algorithm definitions.
Eligible cohort entry dates:
- For US MarketScan, 2012-2018
- For Optum, 2012-2020
- For Medicare Claims Database (Parts A, B and D), 2012-2017
Cohort entry date:
- First TNFi or tofacitinib dispensation/administration date
Inclusion and Exclusion Criteria Common to RWE and RCT-duplicate Cohorts:
Inclusion Criteria
- Patients treated with tofacitinib or TNF inhibitors in IBM MarketScan, Optum, and Medicare fee-for-service
- A minimum of 365 days of continuous enrollment in health plan prior to (and including) the cohort entry date
- Two diagnosis codes for RA in any setting in 365 days baseline period (diagnosis codes between 7 and 365 days apart)
Exclusion Criteria
- Index drug in 365 days prior to cohort entry date (prevalent users)
- Missing data on age or gender
- Admission to nursing facility or hospice on or prior to cohort entry date (ever look-back)
- TNFi users with history of any Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib, or baricitinib) (ever look-back period)
- TNFi users initiating with more than one TNFi on same date
- Tofacitinib users with a prescription of baricitinib, upadacitinib (ever look-back period)
- Tofacitinib users initiating treatment on multiple JAK inhibitors on same day (tofacitinib and baricitinib, tofacitinib and upadacitinib)
Exclusion criteria specific to RWE cohorts:
- Patients less than 18 years of age (MarketScan and Optum) and 65 years of age (Medicare) at cohort entry
Inclusion criteria specific to RCT-duplicate cohorts:
- Patients with at least one methotrexate dispensation (six months look-back period)
- Patients with at least one cardiovascular risk factor (including smoking, hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, family history of ischemic heart disease) (one-year look-back period)
Exclusion criteria specific to RCT-duplicate cohorts:
- Patients less than 50 years of age (MarketScan and Optum) and 65 years
- Patients recently hospitalized with infections (30-day look-back period)
- Pregnant patients (one year look-back period)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients treated with Tofacitinib
Real-World Evidence (RWE) and RCT-Duplicate
|
First eligible prescription for treating rheumatoid arthritis (RA)
|
Patients treated with TNF inhibitors
Real-World Evidence (RWE) and RCT-Duplicate
|
First eligible prescription for treating rheumatoid arthritis (RA)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first composite cardiovascular endpoint consisting of myocardial infarction or stroke
Time Frame: Through study time period (2012-2020)
|
Myocardial infarction OR Stroke
|
Through study time period (2012-2020)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to myocardial infarction
Time Frame: Through study time period (2012-2020)
|
Through study time period (2012-2020)
|
Time to stroke
Time Frame: Through study time period (2012-2020)
|
Through study time period (2012-2020)
|
Time to heart failure hospitalization
Time Frame: Through study time period (2012-2020)
|
Through study time period (2012-2020)
|
Time to coronary revascularization
Time Frame: Through study time period (2012-2020)
|
Through study time period (2012-2020)
|
Time to all-cause mortality
Time Frame: Through study time period (2012-2020)
|
Through study time period (2012-2020)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rishi Desai, MS, PhD, Assistant Professor of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Dermatologic Agents
- Protein Kinase Inhibitors
- Etanercept
- Adalimumab
- Infliximab
- Golimumab
- Certolizumab Pegol
- Tofacitinib
- Tumor Necrosis Factor Inhibitors
Other Study ID Numbers
- 2011P002580-202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Richard Burt, MDTerminated
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
Clinical Trials on Tofacitinib
-
PfizerCompletedAnkylosing SpondylitisKorea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
-
PfizerCompleted
-
PfizerCompletedPlaque PsoriasisUnited States
-
PfizerCompleted
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingDiaphragm InjuryUnited States
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis
-
PfizerCompleted
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine